Adverse Events of Novel Agents in Multiple Myeloma

This study focused on the evolution of treatment options for multiple myeloma, which now include immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), monoclonal antibodies (mAbs), and a histone deacetylase inhibitor (HDACi). The study analyzed pivotal clinical trials to understand the side effects of these drugs – emphasizing the importance of considering the side effects within the context of the disease, drug combinations, and supportive measures – and discussed strategies for their prevention and management. The study also highlighted the need for consistent reporting standards for adverse events (AEs) to better understand their quality, incidence, and severity.

Researchers underscored the importance of monitoring for thromboembolic complications, peripheral neuropathy, and infusion-related reactions, especially with mAbs like elotuzumab and daratumumab. Management strategies include dose modifications, prophylactic measures, and patient education regarding risks and symptoms. This comprehensive understanding of the side effects and management strategies associated with novel myeloma therapies is crucial for optimizing patient outcomes and minimizing treatment-related complications.

Reference: Ludwig H, Delforge M, Facon T, etal. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.  Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. PMID: 29720735; PMCID: PMC6035147.

Related Articles